Ultraschall in Med 2012; 33(6): 597-598
DOI: 10.1055/s-0032-1313141
Case Report
© Georg Thieme Verlag KG Stuttgart · New York

Anaphylactic Shock Induced by Sulphur Hexafluoride in an Individual with no History of Heart Disease: Case Report and Literature review

Schwefelhexafluorid-induzierter allergischer Schock bei einer Person ohne Vorgeschichte einer Herzerkrankung
F. M. Solivetti
F. Elia
F. Musicco
A. C. Bonagura
N. Di Leo
J. Iera
Francesco Drudi
Further Information

Publication History

05 April 2012

09 July 2012

Publication Date:
24 August 2012 (eFirst)


Ultrasound Contrast agents (UCA) are considered with a low incidence of side effects (Piscaglia F et al. Ultraschall in Med 2011; 33: 33 – 59). According to the results of clinical trials conducted on SonoVue®, the incidence of adverse events was 10.8 %. The incidence of severe adverse events was very low (0.4 %), with only 3 cases of death (0.06 % of all adverse events) for which it was not possible to exclude an association with SonoVue® (http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM252 880.pdf); however, in all these cases, the individuals were already at high risk of severe heart complications which may have been the actual cause of death. SonoVue® is contraindicated in the following individuals: individuals with known hypersensitivity to sulphur hexafluoride or any of its excipients; individuals with recent acute coronary syndrome or unstable cardiac ischemia; individuals with right-left shunt, with severe pulmonary hypertension, uncontrolled hypertension or adult respiratory distress syndrome; pregnant women or women who are breastfeeding. To date, there are no reports of severe adverse events in healthy individuals. We report a case of a severe adverse event in an individual with no clinically significant cardiac or pulmonary pathologies.